UCB’s psoriasis candidate, Bimekizumab has shown promising clinical data vs. J&J’s Stelara. While this increases the probability that the drug could hit the market in Q1 21, its real competition in the overly-crowded space would come from Novartis’s Cosentyx. Bimekizumab should report head-to-head data with Cosentyx in the next few weeks and, if it is found to be superior, we will increase our peak sales potential for Bimekizumab by €500m to €2bn.
16 Jun 2020
UCB’s psoriasis candidate is racing ahead of its rivals
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
UCB’s psoriasis candidate is racing ahead of its rivals
UCB S.A. (UCB:WBO) | 0 0 1.1% | Mkt Cap: 13,141m
- Published:
16 Jun 2020 -
Author:
Rishabh Kochar -
Pages:
3
UCB’s psoriasis candidate, Bimekizumab has shown promising clinical data vs. J&J’s Stelara. While this increases the probability that the drug could hit the market in Q1 21, its real competition in the overly-crowded space would come from Novartis’s Cosentyx. Bimekizumab should report head-to-head data with Cosentyx in the next few weeks and, if it is found to be superior, we will increase our peak sales potential for Bimekizumab by €500m to €2bn.